TAS::75 0849::TAS;SBIR TOPIC 255, PHASE II "A STRADOBODY DIRECTED AGAINST LOW E

Information

• Research Project
• 8351825

• ApplicationId

  8351825

• Core Project Number

  261201100103C-0-0-1

• Full Project Number

  261201100103C-0-0-1

• Serial Number

  0

• FOA Number

• Sub Project Id

• Project Start Date

  9/29/2011 - 13 years ago

• Project End Date

  9/28/2013 - 11 years ago

• Program Officer Name

• Budget Start Date

  -

• Budget End Date

  -

• Fiscal Year

  2011

• Support Year

• Suffix

• Award Notice Date

  -

Organizations

• GLIKNIK INC.

Background Information [unreadable] Rituxan[unreadable] and Herceptin[unreadable] are multi-billion dollar products that are useful in lymphoma and breast cancer. However, significant unmet medical need persists for certain populations such as recurrent indolent NHL, HER2 IHC 2+ patients, and treatment of patients with the FcgR3a 158 F/F polymorphism. This contract proposal is designed to: a) generate a novel anti-CD20 or anti-HER2 neu compound that will advance towards clinical trial and prove to have advantages over the currently marketed antibody compound, and b) establish a new therapeutic approach to cancer.

IC Name

• Activity

  N44

• Administering IC

  CA

• Application Type

• Direct Cost Amount

• Indirect Cost Amount

• Total Cost

  1500000

• Sub Project Total Cost

• ARRA Funded

  False

• CFDA Code

  395

• Ed Inst. Type

• Funding ICs

  NCI:1500000\

• Funding Mechanism

  Contracts, Extramural

• Study Section

• Study Section Name

• Organization Name

  GLIKNIK, INC.

• Organization Department

• Organization DUNS

  824766062

• Organization City

  BALTIMORE

• Organization State

  MD

• Organization Country

  UNITED STATES

• Organization Zip Code

  212011194

• Organization District

  UNITED STATES